J. Goldman & Co’s Kite Pharma, Inc. KITE Stock Holding History

J. Goldman & Co’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11,200	Closed	-$879K	–	465
2017 Q1	$879K	Buy	+11,200	New	+$693K	0.04%	256

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

J. Goldman & Co's KITE Position: Q2 2017 in Review

J. Goldman & Co sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 11,200 shares — an estimated $879K sold.

J. Goldman & Co first reported a position in KITE in Q1 2017 and held it in 1 quarter. The position peaked at $879K in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

J. Goldman & Co reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
J. Goldman & Co sold 11,200 Kite Pharma, Inc. shares in Q2 2017, an estimated $879K.
J. Goldman & Co first reported a position in Kite Pharma, Inc. in Q1 2017 and held it in 1 quarter.
J. Goldman & Co's Kite Pharma, Inc. position peaked at $879K in Q1 2017.
220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on J. Goldman & Co's 13F filing for Q2 2017, filed 14 Aug 2017.